Conventional CD4+ T cells present bacterial antigens to induce cytotoxic and memory CD8+ T cell responses

Bacterial phagocytosis and antigen cross-presentation to activate CD8+ T cells are principal functions of professional antigen presenting cells. However, conventional CD4+ T cells also capture and kill bacteria from infected dendritic cells in a process termed transphagocytosis (also known as transi...

Descripción completa

Detalles Bibliográficos
Autores: Cruz-Adalia, Aránzazu, Ramirez-Santiago, Guillermo, Osuna-Pérez, Jesús, Torres-Torresano, Mónica, Zorita, Virginia, Martínez-Riaño, Ana, Boccasavia, Viola, Borroto, Aldo, Martinez del Hoyo, Gloria, Gonzalez-Granado, Jose Maria, Alarcón, Balbino, Sanchez-Madrid, Francisco, Veiga, Esteban
Tipo de recurso: artículo
Fecha de publicación:2017
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/7229
Acceso en línea:http://hdl.handle.net/20.500.12105/7229
Access Level:acceso abierto
Palabra clave:Animals
Antigen Presentation
Antigens, Bacterial
CD4-Positive T-Lymphocytes
CD8-Positive T-Lymphocytes
Cells, Cultured
Cross-Priming
Cytotoxicity, Immunologic
Immunologic Memory
Immunological Synapses
Mice, Inbred C57BL
Mice, Transgenic
Phagocytosis
Programmed Cell Death 1 Receptor
Descripción
Sumario:Bacterial phagocytosis and antigen cross-presentation to activate CD8+ T cells are principal functions of professional antigen presenting cells. However, conventional CD4+ T cells also capture and kill bacteria from infected dendritic cells in a process termed transphagocytosis (also known as transinfection). Here, we show that transphagocytic T cells present bacterial antigens to naive CD8+ T cells, which proliferate and become cytotoxic in response. CD4+ T-cell-mediated antigen presentation also occurs in vivo in the course of infection, and induces the generation of central memory CD8+ T cells with low PD-1 expression. Moreover, transphagocytic CD4+ T cells induce protective anti-tumour immune responses by priming CD8+ T cells, highlighting the potential of CD4+ T cells as a tool for cancer immunotherapy.